Clarity Pharma Shares Up about the result of the clinical study, UoQ Supply Deal – Capital Brief

The news: The stocks of Clarity Pharmaceuticals increased in the early trade after the radiopharmaceutical company at the clinical level rose by more than 7%to achieve positive clinical study results for his prostate cancer treatment Cu-Sar-Bispsma and signed a new supply contract with the University of Queensland.

The numbers: The Clarity shares initially rose by more than 7% to $ 3.18, but were only 0.7% higher at $ 2.99 at 10:45 a.m. after they had withdrawn by almost 30% in the past 12 months.

The context: Clarity described the results from the dose escalation phase of their safe study “extraordinary” after observing “impressive signs of effectiveness” in treatment with a test stage. Cu-Sar-Bispsma will now go through the second phase of his Theranostic course.

In the meantime, Clarity signed a supply agreement with the University of Queensland for Copper Isotope Copper-64 to support the clinical studies of the Cu-Sar-Bisps in Australia. The deal will also support the introduction of two other Theranostic preclinical programs, said the company.